全文获取类型
收费全文 | 516篇 |
免费 | 30篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 18篇 |
妇产科学 | 65篇 |
基础医学 | 79篇 |
口腔科学 | 6篇 |
临床医学 | 28篇 |
内科学 | 101篇 |
皮肤病学 | 17篇 |
神经病学 | 41篇 |
特种医学 | 2篇 |
外科学 | 48篇 |
综合类 | 2篇 |
预防医学 | 66篇 |
眼科学 | 6篇 |
药学 | 32篇 |
中国医学 | 2篇 |
肿瘤学 | 33篇 |
出版年
2023年 | 11篇 |
2022年 | 17篇 |
2021年 | 21篇 |
2020年 | 18篇 |
2019年 | 22篇 |
2018年 | 23篇 |
2017年 | 14篇 |
2016年 | 13篇 |
2015年 | 16篇 |
2014年 | 23篇 |
2013年 | 22篇 |
2012年 | 42篇 |
2011年 | 37篇 |
2010年 | 21篇 |
2009年 | 13篇 |
2008年 | 21篇 |
2007年 | 18篇 |
2006年 | 14篇 |
2005年 | 10篇 |
2004年 | 14篇 |
2003年 | 13篇 |
2002年 | 8篇 |
2001年 | 7篇 |
2000年 | 6篇 |
1999年 | 5篇 |
1998年 | 3篇 |
1995年 | 1篇 |
1994年 | 3篇 |
1993年 | 4篇 |
1992年 | 9篇 |
1991年 | 2篇 |
1990年 | 8篇 |
1989年 | 6篇 |
1988年 | 5篇 |
1987年 | 6篇 |
1986年 | 7篇 |
1985年 | 8篇 |
1984年 | 9篇 |
1983年 | 10篇 |
1982年 | 5篇 |
1981年 | 10篇 |
1980年 | 3篇 |
1979年 | 6篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1973年 | 2篇 |
1968年 | 1篇 |
排序方式: 共有549条查询结果,搜索用时 15 毫秒
41.
42.
Iversen KK Teisner AS Teisner B Kliem A Bay M Kirk V Nielsen H Boesgaard S Grande P Clemmensen P 《Clinical biochemistry》2008,41(7-8):548-553
ObjectivePAPP-A is a promising new marker in coronary heart disease. It is important to investigate its specificity in order to establish its clinical utility as a marker of coronary heart disease.Design and methodsPAPP-A was measured within 24 h following hospital admission in 1448 consecutive patients admitted with diagnoses other than acute coronary syndromes.ResultsPAPP-A was detectable (≥ 4.0 mIU/L) in 278 (19.2%) patients, among whom the mean level was 6.3 mIU/L (95% C.I., 6.1–6.5 mIU/L). The 95 and 99 percentiles for PAPP-A were 7.3 and 9.4 mIU/L, respectively. There was no difference in the mean PAPP-A of different diagnoses (p = 0.33). None of the specific diagnoses known to influence established coronary markers appeared to influence the level of circulating PAPP-A.ConclusionPAPP-A is low in patients without known coronary heart disease. PAPP-A levels seem to be a potentially highly specific marker for heart disease. 相似文献
43.
Andres AM Thompson J Grant W Botha J Sunderman B Antonson D Langnas A Sudan D 《Transplantation》2008,85(9):1294-1299
BACKGROUND: Feasibility of repeat lengthening has been demonstrated in animals, but in humans, none of the three clinical case reports have achieved enteral autonomy after secondary lengthening with serial transverse enteroplasty (STEP). PATIENTS AND METHODS: Institutional Review Board approved retrospective review of a single center series of repeat intestinal lengthening after prior Bianchi lengthening or STEP. Outcome measures examined include patient survival, weaning from parenteral nutrition, and need for intestinal transplantation. RESULTS: Repeat lengthening with STEP was performed 16 times in 14 patients including 2 adults and 7 male patients after prior Bianchi (n=7) and prior STEP (n=7). Median time after initial lengthening to reSTEP was 12 months (2 months-15 years). Median remnant bowel length before initial lengthening was 35 cm (15-110), before reSTEP was 56.5 cm (27-100) and final length after reSTEP was 90 cm (39-120). Survival is 100% with a median follow-up of 14.5 months (1-65 months). Discontinuation of parenteral nutrition (PN) after reSTEP was achieved in 6 of 14 (43%) patients at a median of 3 months (0.5-13 months) after reSTEP. Intestinal transplant salvage was performed in four patients at 7, 9, 13 months, and 4.6 years, respectively, after reSTEP. All four of those undergoing intestinal transplantation have also subsequently discontinued PN. CONCLUSIONS: Repeat lengthening is technically feasible after either of the available surgical lengthening procedures (Bianchi and STEP). In the stable patient, who is unable to wean from PN, repeat lengthening led to discontinuation of TPN in almost half of these carefully selected patients and does not preclude intestinal transplantation. 相似文献
44.
45.
46.
47.
Langerhans cell markers CD1a and CD207 are the most rapidly responding genes in lesional psoriatic skin following adalimumab treatment 下载免费PDF全文
Line Raaby Cecilia Rosada Ane Langkilde Kristina Lystlund Lauridsen Hanne Vinter Pernille Ommen Rasmus Boye Kjellerup Claus Johansen Lars Iversen 《Experimental dermatology》2017,26(9):804-810
TNFα‐, IL‐23‐ and IL‐17‐targeting drugs are highly effective in the treatment of psoriasis. However, the precise molecular mechanism remains unknown. In psoriatic skin, the presence of Langerhans cells (LCs) is reduced, but the role of LC is poorly understood. The purpose of this study was to investigate the impact of TNFα and IL‐23/IL‐17 on the presence of LC in the skin during treatment. Therefore, psoriatic skin was investigated before and after 4 days of adalimumab or ustekinumab treatment. Furthermore, TNFα and IL‐17A stimulation was investigated in an ex vivo model of epidermis and dermis from healthy normal skin kept in cultures at an air‐liquid interphase for 4 days. In a gene array analysis, we found that the two LC markers, CD1a and CD207, were among the most up‐ or downregulated genes in psoriatic skin after anti‐TNFα therapy. Validation showed that both mRNA expression and protein level followed the same pattern and became significantly upregulated after 4 days of treatment. No changes were seen after ustekinumab treatment. In the ex vivo skin model, a decrease in the CD1a level was seen after TNFα stimulation and it was caused by LC migration from epidermis. No response in LC migration was seen after IL‐17A stimulation. Taken together, we demonstrated that changes in the LC level in epidermis precede the histological and clinical changes during adalimumab treatment in psoriatic skin. Furthermore, TNFα plays a prominent role in orchestrating LC migration in the skin. This seems not to be the true for the IL‐23/IL‐17A pathway. 相似文献
48.
49.
Melissa A. Russell Christer Janson Francisco Gómez Real Ane Johannessen Marie Waatevik Bryndis Benediktsdóttir 《The Journal of asthma》2017,54(9):938-945
Objective: To investigate the impact of physical activity on asthma in middle-aged adults, in one longitudinal analysis, and one multi-centre cross-sectional analysis. Methods: The Respiratory Health in Northern Europe (RHINE) is a population-based postal questionnaire cohort study. Physical activity, height and weight were self-reported in Bergen, Norway, at RHINE II (1999–2001) and all centres at RHINE III (2010–2012). A longitudinal analysis of Bergen data investigated the association of baseline physical activity with follow-up asthma, incident asthma and symptoms, using logistic and zero-inflated Poisson regression (n = 1782). A cross-sectional analysis of all RHINE III centres investigated the association of physical activity with concurrent asthma and symptoms (n = 13,542) using mixed-effects models. Body mass index (BMI) was categorised (<20, 20–24.99, 25–29.99, 30+ kg/m2) and physical activity grouped by amount and frequency of lighter (no sweating/heavy breathing) and vigorous (sweating/heavy breathing) activity. Results: In the Bergen longitudinal analysis, undertaking light activity 3+ times/week at baseline was associated with less follow-up asthma (odds ratio [OR] 0.44, 95% confidence interval [CI] 0.22, 0.89), whilst an effect from undertaking vigorous activity 3+ times/week was not detected (OR 1.22, 95% CI 0.44, 2.76). The associations were attenuated with BMI adjustment. In the all-centre cross-sectional analysis an interaction was found, with the association between physical activity and asthma varying across BMI categories. Conclusion: These findings suggest potential longer-term benefit from lighter physical activity, whilst improvement in asthma outcomes from increasing activity intensity was not evident. Additionally, it appears the benefit from physical activity may differ according to BMI. 相似文献
50.
Ana Jiménez-Zabala Loreto Santa-Marina Mónica Otazua Mikel Ayerdi Ane Galarza Mara Gallastegi Enrique Ulibarrena Amaia Molinuevo Asier Anabitarte Jesús Ibarluzea 《Gaceta sanitaria / S.E.S.P.A.S》2018,32(5):418-424